Reduced adhesion of PBMMCs to endothelium in methylprednisolone-treated MS patients: Preliminary results

M. Gelati, E. Corsini, A. Dufour, E. Ciusani, G. Massa, S. Frigerio, C. Milanese, A. Nespolo, A. Salmaggi

Research output: Contribution to journalArticle


Methylprednisolone (MP) is a synthetic steroid commonly used in the treatment of multiple sclerosis (MS) relapses. It has a wide spectrum of activities on immune cells: it might also act by preventing mononuclear cell/endothelium adhesion. We studied adhesion phenomena between cultured human umbilical vein endothelial cells (HUVECs) and PBMNCs (CD45+, CD14+) from 6 MS patients treated in vivo with MP. We also studied fluctuations in CD11a and CD18 levels on lymphocytes and monocytes, as well as changes in serum sICAM-1 and sVCAM-1 concentrations. After MP treatment, PBMNCs adhesion to endothelium decreased at 3 h, while it went back to baseline levels at 24 h. A tendency to increase in both CD11a and CD18 on the surface of lymphocytes was detected, while an increase in serum sVCAM-1 was seen at 3 h.

Original languageEnglish
Pages (from-to)283-292
Number of pages10
JournalActa Neurologica Scandinavica
Issue number5
Publication statusPublished - 1997



  • Adhesion phenomena
  • Methylprednisolone
  • Multiple sclerosis
  • SICAM- 1
  • SVCAM-1

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this